These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 18508797)

  • 41. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imatinib resistance in CML.
    Volpe G; Panuzzo C; Ulisciani S; Cilloni D
    Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
    Schafhausen P; Dierlamm J; Bokemeyer C; Bruemmendorf TH; Bacher U; Zander AR; Schnittger S; Hochhaus A
    Cancer Genet Cytogenet; 2009 Feb; 189(1):63-7. PubMed ID: 19167615
    [No Abstract]   [Full Text] [Related]  

  • 44. Hypolipemiant besides antileukemic effect of imatinib mesylate.
    Gologan R; Constantinescu G; Georgescu D; Ostroveanu D; Vasilache D; Dobrea C; Iancu D; Popov V
    Leuk Res; 2009 Sep; 33(9):1285-7. PubMed ID: 19327828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
    Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
    Park TS; Cheong JW; Kim SJ; Lee KW; Song J; Lee KA; Suh B; Song S; Choi JR
    Cancer Genet Cytogenet; 2009 Apr; 190(1):46-8. PubMed ID: 19264234
    [No Abstract]   [Full Text] [Related]  

  • 48. [Major molecular response to imatinib in a patient with acute mixed lineage leukemia expressing a novel BCR/ABL transcript].
    Liu HX; Cao XY; Tong CR; Wu T; Wang T; Fan QZ; Wu P; Zhang X; Cai P; Zhu P
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):220-3. PubMed ID: 19552835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.
    Sumi M; Tauchi T; Sashida G; Shoji N; Gotoh A; Itoh Y; Miyazawa K; Kimura Y; Ohyashiki JH; Ohyashiki K
    Clin Lab Haematol; 2005 Dec; 27(6):416-7. PubMed ID: 16307547
    [No Abstract]   [Full Text] [Related]  

  • 50. Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib.
    Schalk E; Neum S; Kranz S; Scheinpflug K; Mohren M
    Leuk Res; 2009 Mar; 33(3):e6-7. PubMed ID: 18466968
    [No Abstract]   [Full Text] [Related]  

  • 51. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.
    Grey A; O'Sullivan S; Reid IR; Browett P
    N Engl J Med; 2006 Dec; 355(23):2494-5. PubMed ID: 17151376
    [No Abstract]   [Full Text] [Related]  

  • 52. CMV-induced hemorrhagic cystitis as a complication of peripheral blood stem cell transplantation: case report.
    Tutuncuoglu SO; Yanovich S; Ozdemirli M
    Bone Marrow Transplant; 2005 Aug; 36(3):265-6. PubMed ID: 15937503
    [No Abstract]   [Full Text] [Related]  

  • 53. [Metabolic processes in bones following partial gastrectomy].
    Gburek Z; Gasińska T
    Wiad Lek; 1971 Feb; 24(4):309-14. PubMed ID: 5552294
    [No Abstract]   [Full Text] [Related]  

  • 54. Does magnesium make bones stronger? My wife is 72 and she's taking magnesium supplements for her bones.
    Mayo Clin Health Lett; 2006 May; 24(5):8. PubMed ID: 16703661
    [No Abstract]   [Full Text] [Related]  

  • 55. [Determination of laying time of skeletons].
    Dufková J
    Beitr Gerichtl Med; 1982; 40():189-95. PubMed ID: 7165636
    [No Abstract]   [Full Text] [Related]  

  • 56. [Bone changes in chronic leukemias and their diagnosis by roentgenography].
    SVAB V; FILSAKOVA E
    Cas Lek Cesk; 1952 May; 91(18):534-40. PubMed ID: 14390214
    [No Abstract]   [Full Text] [Related]  

  • 57. [Bone changes in acute leukemia].
    ANTIC M; RADOJICIC B
    Srp Arh Celok Lek; 1963 Feb; 91():217-21. PubMed ID: 14013323
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case-control study.
    Cai J; Liu H; Chen Y; Yu J; Gao J; Jiang H; Zhai X; Ju X; Wu X; Wang N; Tian X; Liang C; Fang Y; Zhou F; Li H; Sun L; Yang L; Guo J; Liu A; Li CK; Zhu Y; Tang J; Yang JJ; Shen S; Cheng C; Pui CH
    Lancet Reg Health West Pac; 2023 Sep; 38():100818. PubMed ID: 37790080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma.
    Paragliola RM; Torino F; Barnabei A; Iannantuono GM; Corsello A; Locantore P; Corsello SM
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.
    O'Sullivan S; Tay ML; Lin JM; Bava U; Callon K; Cornish J; Naot D; Grey A
    PLoS One; 2016; 11(10):e0164727. PubMed ID: 27737004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.